drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.71k | drug2_id int64 1 1.71k | drug1_name stringlengths 4 31 | drug2_name stringlengths 4 31 | drug1_desc stringlengths 27 1.09k ⌀ | drug2_desc stringlengths 27 1.06k ⌀ | label stringlengths 58 191 | label_idx int64 0 85 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 2.58k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06267 | DB00227 | 344 | 267 | Udenafil | Lovastatin | Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada. | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | The metabolism of Lovastatin can be decreased when combined with Udenafil. | 46 | [
[
[
344,
69,
267
]
],
[
[
344,
6,
4590
],
[
4590,
160,
267
]
],
[
[
344,
180,
147
],
[
147,
26,
267
]
],
[
[
344,
251,
225
],
[
225,
... | [
[
[
"Udenafil",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Udenafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Udena... | Udenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lovastatin (Compound)
Udenafil can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Lovastatin
Udenafil may decrease the serum concentration of Bosentan and Bosentan can increase the metabolism of Lovastatin
Udenafi... |
DB00869 | DB12332 | 144 | 381 | Dorzolamide | Rucaparib | Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | The metabolism of Rucaparib can be decreased when combined with Dorzolamide. | 46 | [
[
[
144,
69,
381
]
],
[
[
144,
180,
177
],
[
177,
26,
381
]
],
[
[
144,
249,
156
],
[
156,
26,
381
]
],
[
[
144,
71,
161
],
[
161,
2... | [
[
[
"Dorzolamide",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Dorzolamide",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rucaparib"
]
],
... | Dorzolamide can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Rucaparib
Dorzolamide may increase the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Rucaparib
Dorzolamide may increase the severity of adverse effects when combined with Primido... |
DB01367 | DB06262 | 56 | 694 | Rasagiline | Droxidopa | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | The risk or severity of adverse effects can be increased when Rasagiline is combined with Droxidopa. | 48 | [
[
[
56,
71,
694
]
],
[
[
56,
247,
1344
],
[
1344,
155,
694
]
],
[
[
56,
225,
968
],
[
968,
155,
694
]
],
[
[
56,
207,
715
],
[
715,
... | [
[
[
"Rasagiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Droxidopa"
]
],
[
[
"Rasagiline",
"{u} may increase the hypertensive activities of {v}",
"Levonordefrin"
],
[
"Levonordefrin",
"{u} (Compound) resembl... | Rasagiline may increase the hypertensive activities of Levonordefrin and Levonordefrin (Compound) resembles Droxidopa (Compound)
Rasagiline may increase the severity of adverse effects when combined with Levodopa and Levodopa (Compound) resembles Droxidopa (Compound)
Rasagiline may increase the hypertensive effects of ... |
DB00838 | DB06717 | 134 | 1,106 | Clocortolone | Fosaprepitant | Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | The serum concentration of Fosaprepitant can be increased when it is combined with Clocortolone. | 72 | [
[
[
134,
95,
1106
]
],
[
[
134,
21,
28379
],
[
28379,
175,
1106
]
],
[
[
134,
251,
1110
],
[
1110,
95,
1106
]
],
[
[
134,
1,
105
],
[
105,... | [
[
[
"Clocortolone",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Clocortolone",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fos... | Clocortolone (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Fosaprepitant (Compound)
Clocortolone may decrease the serum concentration of Enzalutamide and Enzalutamide may increase the serum concentration of Fosaprepitant
Clocortolone (Compound) resembles Flumethasone (Compound) and ... |
DB01092 | DB01182 | 1,348 | 1,318 | Ouabain | Propafenone | A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | The serum concentration of Propafenone can be increased when it is combined with Ouabain. | 72 | [
[
[
1348,
95,
1318
]
],
[
[
1348,
230,
248
],
[
248,
95,
1318
]
],
[
[
1348,
230,
1031
],
[
1031,
1,
1318
]
],
[
[
1348,
230,
1034
],
[
10... | [
[
[
"Ouabain",
"{u} may increase the serum concentration of {v}",
"Propafenone"
]
],
[
[
"Ouabain",
"{u} may increase the bradycardic activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may increase the serum concentration of {v}",
"... | Ouabain may increase the bradycardic activities of Carvedilol and Carvedilol may increase the serum concentration of Propafenone
Ouabain may increase the bradycardic activities of Bevantolol and Bevantolol (Compound) resembles Propafenone (Compound)
Ouabain may increase the bradycardic activities of Esmolol and Esmolol... |
DB01175 | DB09048 | 324 | 476 | Escitalopram | Netupitant | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | The serum concentration of Netupitant can be increased when it is combined with Escitalopram. | 72 | [
[
[
324,
95,
476
]
],
[
[
324,
249,
576
],
[
576,
223,
476
]
],
[
[
324,
69,
1093
],
[
1093,
223,
476
]
],
[
[
324,
185,
297
],
[
297,
... | [
[
[
"Escitalopram",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Escitalopram",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may decrease the metabolism of {v}",
"Net... | Escitalopram may increase the serum concentration of Metoprolol and Metoprolol may decrease the metabolism of Netupitant
Escitalopram may decrease the metabolism of Isoniazid and Isoniazid may decrease the metabolism of Netupitant
Escitalopram may increase the hypoglycemic activities of Tolbutamide and Tolbutamide may ... |
DB00252 | DB08930 | 142 | 1,670 | Phenytoin | Dolutegravir | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | The serum concentration of Dolutegravir can be decreased when it is combined with Phenytoin. | 74 | [
[
[
142,
97,
1670
]
],
[
[
142,
21,
28392
],
[
28392,
175,
1670
]
],
[
[
142,
136,
379
],
[
379,
249,
1670
]
],
[
[
142,
97,
495
],
[
495,... | [
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Dolutegravir"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dolutegravir... | Phenytoin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Dolutegravir (Compound)
Phenytoin may increase the serum concentration of Ranolazine and Phenytoin may decrease the serum concentration of Ranolazine and Ranolazine may increase the serum concentration of Dolutegravir
Phenytoin m... |
DB00288 | DB00677 | 114 | 686 | Amcinonide | Isoflurophate | Amcinonide is a corticosteroid. | An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330... | The risk or severity of adverse effects can be increased when Amcinonide is combined with Isoflurophate. | 48 | [
[
[
114,
71,
686
]
],
[
[
114,
251,
156
],
[
156,
26,
686
]
],
[
[
114,
1,
125
],
[
125,
71,
686
]
],
[
[
114,
155,
107
],
[
107,
71... | [
[
[
"Amcinonide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoflurophate"
]
],
[
[
"Amcinonide",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the m... | Amcinonide may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Isoflurophate
Amcinonide (Compound) resembles Flunisolide (Compound) and Flunisolide may increase the severity of adverse effects when combined with Isoflurophate
Amcinonide (Compound) resembles Fludrocorti... |
DB00850 | DB00177 | 525 | 239 | Perphenazine | Valsartan | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | The metabolism of Valsartan can be decreased when combined with Perphenazine. | 46 | [
[
[
525,
69,
239
]
],
[
[
525,
69,
567
],
[
567,
155,
239
]
],
[
[
525,
6,
7128
],
[
7128,
160,
239
]
],
[
[
525,
7,
13633
],
[
13633,
... | [
[
[
"Perphenazine",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
],
[
[
"Perphenazine",
"{u} may decrease the metabolism of {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Valsartan"
]
],
[... | Perphenazine may decrease the metabolism of Losartan and Losartan (Compound) resembles Valsartan (Compound)
Perphenazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Valsartan (Compound)
Perphenazine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Valsartan (Compound)
Perphenazi... |
DB00273 | DB09071 | 1,108 | 1,013 | Topiramate | Tasimelteon | Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermi... | Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a ... | The risk or severity of adverse effects can be increased when Topiramate is combined with Tasimelteon. | 48 | [
[
[
1108,
71,
1013
]
],
[
[
1108,
246,
674
],
[
674,
30,
1013
]
],
[
[
1108,
192,
1266
],
[
1266,
38,
1013
]
],
[
[
1108,
38,
587
],
[
587... | [
[
[
"Topiramate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tasimelteon"
]
],
[
[
"Topiramate",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeu... | Topiramate may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Tasimelteon
Topiramate may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Tasimelteon
Topirama... |
DB01340 | DB09216 | 550 | 449 | Cilazapril | Tolfenamic acid | Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and o... | Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the... | The risk or severity of adverse effects can be increased when Cilazapril is combined with Tolfenamic acid. | 48 | [
[
[
550,
71,
449
]
],
[
[
550,
236,
161
],
[
161,
26,
449
]
],
[
[
550,
249,
744
],
[
744,
28,
449
]
],
[
[
550,
71,
687
],
[
687,
2... | [
[
[
"Cilazapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Cilazapril",
"{u} may increase the hypotensive activities of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the meta... | Cilazapril may increase the hypotensive activities of Primidone and Primidone can increase the metabolism of Tolfenamic acid
Cilazapril may increase the serum concentration of Edoxaban and Edoxaban may increase the anticoagulant activities of Tolfenamic acid
Cilazapril may increase the severity of adverse effects when ... |
DB01224 | DB01165 | 955 | 1,210 | Quetiapine | Ofloxacin | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Quetiapine may increase the QTc-prolonging activities of Ofloxacin. | 19 | [
[
[
955,
42,
1210
]
],
[
[
955,
21,
28527
],
[
28527,
175,
1210
]
],
[
[
955,
95,
764
],
[
764,
196,
1210
]
],
[
[
955,
42,
183
],
[
183,
... | [
[
[
"Quetiapine",
"{u} may increase the QTc prolonging activities of {v}",
"Ofloxacin"
]
],
[
[
"Quetiapine",
"{u} (Compound) causes {v} (Side Effect)",
"Phosphatase alkaline increased"
],
[
"Phosphatase alkaline increased",
"{u} (Side Effect) ... | Quetiapine (Compound) causes Phosphatase alkaline increased (Side Effect) and Phosphatase alkaline increased (Side Effect) is caused by Ofloxacin (Compound)
Quetiapine may increase the serum concentration of Dasatinib and Dasatinib may increase the QTc prolonging activities of Ofloxacin
Quetiapine may increase the QTc ... |
DB00264 | DB00821 | 576 | 11 | Metoprolol | Carprofen | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects... | Metoprolol may decrease the antihypertensive activities of Carprofen. | 36 | [
[
[
576,
59,
11
]
],
[
[
576,
59,
211
],
[
211,
225,
11
]
],
[
[
576,
249,
744
],
[
744,
28,
11
]
],
[
[
576,
225,
557
],
[
557,
205... | [
[
[
"Metoprolol",
"{u} may decrease the antihypertensive activities of {v}",
"Carprofen"
]
],
[
[
"Metoprolol",
"{u} may decrease the antihypertensive activities of {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may increase the severity of adverse... | Metoprolol may decrease the antihypertensive activities of Ketoprofen and Ketoprofen may increase the severity of adverse effects when combined with Carprofen
Metoprolol may increase the serum concentration of Edoxaban and Edoxaban may increase the anticoagulant activities of Carprofen
Metoprolol may increase the sever... |
DB01466 | DB01501 | 493 | 918 | Ethylmorphine | Difenoxin | A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combina... | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Difenoxin. | 48 | [
[
[
493,
71,
918
]
],
[
[
493,
225,
942
],
[
942,
71,
918
]
],
[
[
493,
69,
1086
],
[
1086,
1,
918
]
],
[
[
493,
71,
941
],
[
941,
1... | [
[
[
"Ethylmorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difenoxin"
]
],
[
[
"Ethylmorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
... | Ethylmorphine may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate may increase the severity of adverse effects when combined with Difenoxin
Ethylmorphine may decrease the metabolism of Clotrimazole and Clotrimazole (Compound) resembles Difenoxin (Compound)
Ethylmorphine may i... |
DB00264 | DB00393 | 576 | 503 | Metoprolol | Nimodipine | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | The risk or severity of adverse effects can be increased when Metoprolol is combined with Nimodipine. | 48 | [
[
[
576,
71,
503
]
],
[
[
576,
71,
472
],
[
472,
155,
503
]
],
[
[
576,
236,
444
],
[
444,
155,
503
]
],
[
[
576,
95,
385
],
[
385,
... | [
[
[
"Metoprolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nimodipine"
]
],
[
[
"Metoprolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} (Co... | Metoprolol may increase the severity of adverse effects when combined with Isradipine and Isradipine (Compound) resembles Nimodipine (Compound)
Metoprolol may increase the hypotensive activities of Lercanidipine and Lercanidipine (Compound) resembles Nimodipine (Compound)
Metoprolol may increase the serum concentration... |
DB01081 | DB00750 | 942 | 917 | Diphenoxylate | Prilocaine | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165) | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prilocaine. | 48 | [
[
[
942,
71,
917
]
],
[
[
942,
91,
1334
],
[
1334,
1,
917
]
],
[
[
942,
184,
674
],
[
674,
30,
917
]
],
[
[
942,
38,
1257
],
[
1257,
... | [
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prilocaine"
]
],
[
[
"Diphenoxylate",
"{u} may increase the analgesic activities of {v}",
"Diethylpropion"
],
[
"Diethylpropion",
"{u} (Compound) r... | Diphenoxylate may increase the analgesic activities of Diethylpropion and Diethylpropion (Compound) resembles Prilocaine (Compound)
Diphenoxylate can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Prilocaine
Diphenoxylate may increase the central nervous system d... |
DB01283 | DB01397 | 349 | 808 | Lumiracoxib | Magnesium salicylate | Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have ... | Magnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate,... | The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Magnesium salicylate. | 48 | [
[
[
349,
71,
808
]
],
[
[
349,
225,
780
],
[
780,
155,
808
]
],
[
[
349,
6,
7784
],
[
7784,
160,
808
]
],
[
[
349,
182,
677
],
[
677,
... | [
[
[
"Lumiracoxib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium salicylate"
]
],
[
[
"Lumiracoxib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nepafenac"
],
[
"Nepafenac",
... | Lumiracoxib may increase the severity of adverse effects when combined with Nepafenac and Nepafenac (Compound) resembles Magnesium salicylate (Compound)
Lumiracoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Magnesium salicylate (Compound)
Lumiracoxib may increase the anticoagulant activities of Dabigat... |
DB06148 | DB01200 | 16 | 247 | Mianserin | Bromocriptine | A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine]. | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin. | 69 | [
[
[
16,
92,
247
]
],
[
[
16,
6,
11458
],
[
11458,
160,
247
]
],
[
[
16,
21,
28474
],
[
28474,
175,
247
]
],
[
[
16,
92,
150
],
[
150,
... | [
[
[
"Mianserin",
"{u} may decrease the therapeutic efficacy of {v}",
"Bromocriptine"
]
],
[
[
"Mianserin",
"{u} (Compound) binds {v} (Gene)",
"HTR7"
],
[
"HTR7",
"{u} (Gene) is bound by {v} (Compound)",
"Bromocriptine"
]
],
[
... | Mianserin (Compound) binds HTR7 (Gene) and HTR7 (Gene) is bound by Bromocriptine (Compound)
Mianserin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound)
Mianserin may decrease the therapeutic efficacy of Fosphenytoin and Fosphenytoin can increase the metabolism... |
DB00177 | DB00500 | 239 | 833 | Valsartan | Tolmetin | Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | The risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin. | 48 | [
[
[
239,
71,
833
]
],
[
[
239,
223,
287
],
[
287,
1,
833
]
],
[
[
239,
225,
975
],
[
975,
155,
833
]
],
[
[
239,
223,
628
],
[
628,
... | [
[
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolmetin"
]
],
[
[
"Valsartan",
"{u} may decrease the metabolism of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} (Compound) resembles {v} (Compound)",
... | Valsartan may decrease the metabolism of Zolpidem and Zolpidem (Compound) resembles Tolmetin (Compound)
Valsartan may increase the severity of adverse effects when combined with Tolcapone and Tolcapone (Compound) resembles Tolmetin (Compound)
Valsartan may decrease the metabolism of Suprofen and Suprofen may increase t... |
DB09079 | DB13874 | 1,231 | 323 | Nintedanib | Enasidenib | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | The serum concentration of Enasidenib can be increased when it is combined with Nintedanib. | 72 | [
[
[
1231,
95,
323
]
],
[
[
1231,
251,
147
],
[
147,
26,
323
]
],
[
[
1231,
95,
59
],
[
59,
223,
323
]
],
[
[
1231,
95,
376
],
[
376,
... | [
[
[
"Nintedanib",
"{u} may increase the serum concentration of {v}",
"Enasidenib"
]
],
[
[
"Nintedanib",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Enaside... | Nintedanib may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Enasidenib
Nintedanib may increase the serum concentration of Quinidine and Quinidine may decrease the metabolism of Enasidenib
Nintedanib may increase the serum concentration of Ergometrine and Ergometrine may i... |
DB00937 | DB00985 | 1,334 | 976 | Diethylpropion | Dimenhydrinate | A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290) | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Diethylpropion may decrease the sedative activities of Dimenhydrinate. | 75 | [
[
[
1334,
98,
976
]
],
[
[
1334,
98,
76
],
[
76,
1,
976
]
],
[
[
1334,
98,
989
],
[
989,
225,
976
]
],
[
[
1334,
21,
28463
],
[
28463,
... | [
[
[
"Diethylpropion",
"{u} may decrease the sedative activities of {v}",
"Dimenhydrinate"
]
],
[
[
"Diethylpropion",
"{u} may decrease the sedative activities of {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)... | Diethylpropion may decrease the sedative activities of Benzatropine and Benzatropine (Compound) resembles Dimenhydrinate (Compound)
Diethylpropion may decrease the sedative activities of Cyclizine and Cyclizine may increase the severity of adverse effects when combined with Dimenhydrinate
Diethylpropion (Compound) caus... |
DB00228 | DB00807 | 1,004 | 926 | Enflurane | Proparacaine | Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.[L13646,L13649] Unlike its other inhalational anesthetic counterparts including [isoflurane] and [halothane], enflurane is known to induce seizure activity. In addition, it... | Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt. | The risk or severity of adverse effects can be increased when Enflurane is combined with Proparacaine. | 48 | [
[
[
1004,
71,
926
]
],
[
[
1004,
184,
674
],
[
674,
30,
926
]
],
[
[
1004,
192,
543
],
[
543,
38,
926
]
],
[
[
1004,
38,
405
],
[
405,
... | [
[
[
"Enflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Proparacaine"
]
],
[
[
"Enflurane",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeut... | Enflurane can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Proparacaine
Enflurane may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Proparacaine
Enfluran... |
DB09279 | DB08941 | 1,363 | 733 | Fimasartan | Isoxsuprine | Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed u... | A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor. | The risk or severity of adverse effects can be increased when Fimasartan is combined with Isoxsuprine. | 48 | [
[
[
1363,
71,
733
]
],
[
[
1363,
71,
355
],
[
355,
71,
733
]
],
[
[
1363,
71,
745
],
[
745,
1,
733
]
],
[
[
1363,
52,
828
],
[
828,
... | [
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoxsuprine"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
... | Fimasartan may increase the severity of adverse effects when combined with Phenoxybenzamine and Phenoxybenzamine may increase the severity of adverse effects when combined with Isoxsuprine
Fimasartan may increase the severity of adverse effects when combined with Fenoprofen and Fenoprofen (Compound) resembles Isoxsupri... |
DB01567 | DB09017 | 1,270 | 930 | Fludiazepam | Brotizolam | Fludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a scheduled drug in the U.S., but is approved for use in Japan. | Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatme... | The risk or severity of adverse effects can be increased when Fludiazepam is combined with Brotizolam. | 48 | [
[
[
1270,
116,
930
]
],
[
[
1270,
155,
585
],
[
585,
1,
930
]
],
[
[
1270,
1,
1273
],
[
1273,
1,
930
]
],
[
[
1270,
246,
674
],
[
674,
... | [
[
[
"Fludiazepam",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Fludiazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
... | Fludiazepam (Compound) resembles Brotizolam (Compound) and
Fludiazepam (Compound) resembles Midazolam (Compound) and Midazolam (Compound) resembles Brotizolam (Compound)
Fludiazepam (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Brotizolam (Compound)
Fludiazepam may decrease the therap... |
DB01395 | DB00500 | 1,117 | 833 | Drospirenone | Tolmetin | Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, dros... | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Drospirenone may increase the hyperkalemic activities of Tolmetin. | 67 | [
[
[
1117,
90,
833
]
],
[
[
1117,
90,
628
],
[
628,
225,
833
]
],
[
[
1117,
6,
7784
],
[
7784,
160,
833
]
],
[
[
1117,
21,
28549
],
[
28549... | [
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Tolmetin"
]
],
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Suprofen"
],
[
"Suprofen",
"{u} may increase the severity of adverse effects ... | Drospirenone may increase the hyperkalemic activities of Suprofen and Suprofen may increase the severity of adverse effects when combined with Tolmetin
Drospirenone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Tolmetin (Compound)
Drospirenone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect)... |
DB00346 | DB00221 | 278 | 727 | Alfuzosin | Isoetharine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Isoetharine is a relatively selective beta-2 adrenergic agonist. It is a catechol-like agent. Isoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma. | Alfuzosin may decrease the vasoconstricting activities of Isoetharine. | 4 | [
[
[
278,
27,
727
]
],
[
[
278,
82,
715
],
[
715,
1,
727
]
],
[
[
278,
27,
705
],
[
705,
1,
727
]
],
[
[
278,
27,
710
],
[
710,
155,
... | [
[
[
"Alfuzosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Isoetharine"
]
],
[
[
"Alfuzosin",
"{u} may increase the hypotensive activities of {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} (Compound) resembles {v} (Compound)",
... | Alfuzosin may increase the hypotensive activities of Methyldopa and Methyldopa (Compound) resembles Isoetharine (Compound)
Alfuzosin may decrease the vasoconstricting activities of Salbutamol and Salbutamol (Compound) resembles Isoetharine (Compound)
Alfuzosin may decrease the vasoconstricting activities of Procaterol ... |
DB00755 | DB08873 | 172 | 1,113 | Tretinoin | Boceprevir | Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin ex... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | The metabolism of Boceprevir can be decreased when combined with Tretinoin. | 46 | [
[
[
172,
69,
1113
]
],
[
[
172,
6,
4590
],
[
4590,
160,
1113
]
],
[
[
172,
7,
8549
],
[
8549,
160,
1113
]
],
[
[
172,
21,
28503
],
[
28503... | [
[
[
"Tretinoin",
"{u} may decrease the metabolism of {v}",
"Boceprevir"
]
],
[
[
"Tretinoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Tre... | Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Tretinoin (Compound) upregulates CTSL (Gene) and CTSL (Gene) is bound by Boceprevir (Compound)
Tretinoin (Compound) causes Hypercalcaemia (Side Effect) and Hypercalcaemia (Side Effect) is caused by Boceprevir (Compound)
Tretino... |
DB09183 | DB09073 | 661 | 1,394 | Dasabuvir | Palbociclib | Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in ... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | The serum concentration of Palbociclib can be increased when it is combined with Dasabuvir. | 72 | [
[
[
661,
95,
1394
]
],
[
[
661,
69,
610
],
[
610,
223,
1394
]
],
[
[
661,
69,
499
],
[
499,
95,
1394
]
],
[
[
661,
95,
1269
],
[
1269,
... | [
[
[
"Dasabuvir",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Dasabuvir",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Palbociclib"
... | Dasabuvir may decrease the metabolism of Atomoxetine and Atomoxetine may decrease the metabolism of Palbociclib
Dasabuvir may decrease the metabolism of Clomipramine and Clomipramine may increase the serum concentration of Palbociclib
Dasabuvir may increase the serum concentration of Stiripentol and Stiripentol may inc... |
DB00327 | DB00768 | 260 | 478 | Hydromorphone | Olopatadine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of [doxepin], which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator ... | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine. | 48 | [
[
[
260,
71,
478
]
],
[
[
260,
71,
970
],
[
970,
1,
478
]
],
[
[
260,
71,
486
],
[
486,
225,
478
]
],
[
[
260,
69,
499
],
[
499,
225... | [
[
[
"Hydromorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olopatadine"
]
],
[
[
"Hydromorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiothixene"
],
[
"Thiothixene",
... | Hydromorphone may increase the severity of adverse effects when combined with Thiothixene and Thiothixene (Compound) resembles Olopatadine (Compound)
Hydromorphone may increase the severity of adverse effects when combined with Doxepin and Doxepin may increase the severity of adverse effects when combined with Olopatad... |
DB01175 | DB01238 | 324 | 932 | Escitalopram | Aripiprazole | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Escitalopram may increase the QTc-prolonging activities of Aripiprazole. | 19 | [
[
[
324,
42,
932
]
],
[
[
324,
69,
648
],
[
648,
249,
932
]
],
[
[
324,
225,
1306
],
[
1306,
71,
932
]
],
[
[
324,
225,
270
],
[
270,
... | [
[
[
"Escitalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Aripiprazole"
]
],
[
[
"Escitalopram",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may increase the serum concentration of {v}",
... | Escitalopram may decrease the metabolism of Nefazodone and Nefazodone may increase the serum concentration of Aripiprazole
Escitalopram may increase the severity of adverse effects when combined with Vilazodone and Vilazodone may increase the severity of adverse effects when combined with Aripiprazole
Escitalopram may ... |
DB06711 | DB00321 | 697 | 262 | Naphazoline | Amitriptyline | Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles[L5804,L5807]. It acts to decrease congestion and is found in many over the counter (OTC) eye drops and nasal preparations[L5804,L5807]. Naphazoline was first developed in 1942 as a nasal formulation for congestion. | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Naphazoline may decrease the antihypertensive activities of Amitriptyline. | 36 | [
[
[
697,
59,
262
]
],
[
[
697,
246,
16
],
[
16,
155,
262
]
],
[
[
697,
6,
2914
],
[
2914,
160,
262
]
],
[
[
697,
21,
29279
],
[
29279,
... | [
[
[
"Naphazoline",
"{u} may decrease the antihypertensive activities of {v}",
"Amitriptyline"
]
],
[
[
"Naphazoline",
"{u} may decrease the therapeutic efficacy of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} (Compound) resembles {v} (Compound)",
... | Naphazoline may decrease the therapeutic efficacy of Mianserin and Mianserin (Compound) resembles Amitriptyline (Compound)
Naphazoline (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Amitriptyline (Compound)
Naphazoline (Compound) causes Intraocular pressure increased (Side Effect) and Intraocular pressure... |
DB01440 | DB01545 | 974 | 948 | gamma-Hydroxybutyric acid | Ethyl loflazepate | Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III dru... | null | The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Ethyl loflazepate. | 48 | [
[
[
974,
71,
948
]
],
[
[
974,
225,
407
],
[
407,
71,
948
]
],
[
[
974,
71,
972
],
[
972,
155,
948
]
],
[
[
974,
71,
259
],
[
259,
7... | [
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethyl loflazepate"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diazepam"
],
[... | gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Diazepam and Diazepam may increase the severity of adverse effects when combined with Ethyl loflazepate
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Halazepam and Halazepam (Compound) r... |
DB00397 | DB01324 | 712 | 1,066 | Phenylpropanolamine | Polythiazide | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Phenylpropanolamine may increase the hypokalemic activities of Polythiazide. | 82 | [
[
[
712,
105,
1066
]
],
[
[
712,
105,
1325
],
[
1325,
1,
1066
]
],
[
[
712,
105,
1049
],
[
1049,
82,
1066
]
],
[
[
712,
105,
1045
],
[
104... | [
[
[
"Phenylpropanolamine",
"{u} may increase the hypokalemic activities of {v}",
"Polythiazide"
]
],
[
[
"Phenylpropanolamine",
"{u} may increase the hypokalemic activities of {v}",
"Quinethazone"
],
[
"Quinethazone",
"{u} (Compound) resembles ... | Phenylpropanolamine may increase the hypokalemic activities of Quinethazone and Quinethazone (Compound) resembles Polythiazide (Compound)
Phenylpropanolamine may increase the hypokalemic activities of Bendroflumethiazide and Bendroflumethiazide may increase the hypotensive activities of Polythiazide
Phenylpropanolamine... |
DB00486 | DB00700 | 1,265 | 462 | Nabilone | Eplerenone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | The risk or severity of adverse effects can be increased when Nabilone is combined with Eplerenone. | 48 | [
[
[
1265,
71,
462
]
],
[
[
1265,
21,
28510
],
[
28510,
175,
462
]
],
[
[
1265,
192,
161
],
[
161,
26,
462
]
],
[
[
1265,
192,
968
],
[
968... | [
[
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eplerenone"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Nabilone (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Eplerenone (Compound)
Nabilone may increase the central nervous system depressant activities of Primidone and Primidone can increase the metabolism of Eplerenone
Nabilone may increase the central nervous system depressant activities... |
DB09279 | DB09038 | 1,363 | 953 | Fimasartan | Empagliflozin | Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed u... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | The risk or severity of adverse effects can be increased when Fimasartan is combined with Empagliflozin. | 48 | [
[
[
1363,
71,
953
]
],
[
[
1363,
71,
63
],
[
63,
185,
953
]
],
[
[
1363,
52,
968
],
[
968,
206,
953
]
],
[
[
1363,
225,
1353
],
[
1353,
... | [
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
... | Fimasartan may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may increase the hypoglycemic activities of Empagliflozin
Fimasartan may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Empaglif... |
DB09295 | DB00744 | 1,442 | 487 | Talniflumate | Zileuton | Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. In addition, it is used in inflammatory conditions such as rheumatoid arthritis. Phase I trials with talniflumate for the treatment of cystic... | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | The risk or severity of adverse effects can be increased when Talniflumate is combined with Zileuton. | 48 | [
[
[
1442,
71,
487
]
],
[
[
1442,
71,
4
],
[
4,
225,
487
]
],
[
[
1442,
71,
687
],
[
687,
28,
487
]
],
[
[
1442,
71,
582
],
[
582,
22... | [
[
[
"Talniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zileuton"
]
],
[
[
"Talniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiaprofenic acid"
],
[
"Tiaprofenic acid",
... | Talniflumate may increase the severity of adverse effects when combined with Tiaprofenic acid and Tiaprofenic acid may increase the severity of adverse effects when combined with Zileuton
Talniflumate may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulan... |
DB01086 | DB09166 | 945 | 480 | Benzocaine | Etizolam | Benzocaine is an ester local anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. It is commonly used for local anesthesia in many over the counter products.[L32454,L32459,L32464] Benzocaine was first used for local anesthesia in dentistry. | Etizolam is a thienodiazepine which is chemically related to benzodiazepine (BDZ) drug class; it differs from BDZs in having a benzene ring replaced with a thiophene ring. It is an agonist at GABA-A receptors and possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. ... | The risk or severity of adverse effects can be increased when Benzocaine is combined with Etizolam. | 48 | [
[
[
945,
71,
480
]
],
[
[
945,
225,
156
],
[
156,
26,
480
]
],
[
[
945,
38,
405
],
[
405,
192,
480
]
],
[
[
945,
192,
1083
],
[
1083,
... | [
[
[
"Benzocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etizolam"
]
],
[
[
"Benzocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u}... | Benzocaine may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Etizolam
Benzocaine may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activi... |
DB00461 | DB00180 | 804 | 125 | Nabumetone | Flunisolide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | The risk or severity of adverse effects can be increased when Nabumetone is combined with Flunisolide. | 48 | [
[
[
804,
71,
125
]
],
[
[
804,
71,
134
],
[
134,
1,
125
]
],
[
[
804,
71,
105
],
[
105,
155,
125
]
],
[
[
804,
21,
28528
],
[
28528,
... | [
[
[
"Nabumetone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunisolide"
]
],
[
[
"Nabumetone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clocortolone"
],
[
"Clocortolone",
"{u... | Nabumetone may increase the severity of adverse effects when combined with Clocortolone and Clocortolone (Compound) resembles Flunisolide (Compound)
Nabumetone may increase the severity of adverse effects when combined with Flumethasone and Flumethasone (Compound) resembles Flunisolide (Compound)
Nabumetone (Compound) ... |
DB00169 | DB00343 | 414 | 461 | Cholecalciferol | Diltiazem | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and... | The metabolism of Diltiazem can be decreased when combined with Cholecalciferol. | 46 | [
[
[
414,
69,
461
]
],
[
[
414,
6,
4590
],
[
4590,
160,
461
]
],
[
[
414,
180,
164
],
[
164,
26,
461
]
],
[
[
414,
69,
1091
],
[
1091,
... | [
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Diltiazem"
]
],
[
[
... | Cholecalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diltiazem (Compound)
Cholecalciferol can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Diltiazem
Cholecalciferol may decrease the metabolism of Dronedarone and Dronedarone may increase the atrioventr... |
DB00877 | DB08933 | 404 | 1,114 | Sirolimus | Luliconazole | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. | The serum concentration of Luliconazole can be increased when it is combined with Sirolimus. | 72 | [
[
[
404,
95,
1114
]
],
[
[
404,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
404,
21,
29330
],
[
29330,
175,
1114
]
],
[
[
404,
225,
1303
],
[
13... | [
[
[
"Sirolimus",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
... | Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Sirolimus (Compound) causes Cellulitis (Side Effect) and Cellulitis (Side Effect) is caused by Luliconazole (Compound)
Sirolimus may increase the severity of adverse effects when combined with Methylergometrine and Methylergo... |
DB00477 | DB00206 | 392 | 925 | Chlorpromazine | Reserpine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Reserpine. | 48 | [
[
[
392,
71,
925
]
],
[
[
392,
223,
230
],
[
230,
213,
925
]
],
[
[
392,
6,
8339
],
[
8339,
160,
925
]
],
[
[
392,
7,
5223
],
[
5223,
... | [
[
[
"Chlorpromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Reserpine"
]
],
[
[
"Chlorpromazine",
"{u} may decrease the metabolism of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensi... | Chlorpromazine may decrease the metabolism of Yohimbine and Yohimbine may decrease the antihypertensive activities of Reserpine
Chlorpromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Reserpine (Compound)
Chlorpromazine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is upregulated by Reserpine (... |
DB00307 | DB00976 | 592 | 528 | Bexarotene | Telithromycin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | The metabolism of Telithromycin can be decreased when combined with Bexarotene. | 46 | [
[
[
592,
69,
528
]
],
[
[
592,
69,
1088
],
[
1088,
42,
528
]
],
[
[
592,
6,
4590
],
[
4590,
160,
528
]
],
[
[
592,
21,
28714
],
[
28714,
... | [
[
[
"Bexarotene",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Bexarotene",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
... | Bexarotene may decrease the metabolism of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Telithromycin
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Bexarotene (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is cause... |
DB00408 | DB01174 | 981 | 164 | Loxapine | Phenobarbital | An antipsychotic agent used in schizophrenia. [PubChem] | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | The risk or severity of adverse effects can be increased when Loxapine is combined with Phenobarbital. | 48 | [
[
[
981,
71,
164
]
],
[
[
981,
71,
821
],
[
821,
225,
164
]
],
[
[
981,
71,
142
],
[
142,
192,
164
]
],
[
[
981,
71,
194
],
[
194,
1... | [
[
[
"Loxapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
]
],
[
[
"Loxapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
],
[
"Ethotoin",
"{u} may incr... | Loxapine may increase the severity of adverse effects when combined with Ethotoin and Ethotoin may increase the severity of adverse effects when combined with Phenobarbital
Loxapine may increase the severity of adverse effects when combined with Phenytoin and Phenytoin may increase the central nervous system depressant... |
DB00969 | DB00705 | 428 | 508 | Alosetron | Delavirdine | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | The metabolism of Delavirdine can be decreased when combined with Alosetron. | 46 | [
[
[
428,
69,
508
]
],
[
[
428,
6,
12128
],
[
12128,
160,
508
]
],
[
[
428,
21,
28475
],
[
28475,
175,
508
]
],
[
[
428,
180,
173
],
[
173,... | [
[
[
"Alosetron",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Alosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
]
],
[
[
"A... | Alosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Delavirdine (Compound)
Alosetron (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Delavirdine (Compound)
Alosetron can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Delavirdine
... |
DB00175 | DB01087 | 350 | 417 | Pravastatin | Primaquine | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | The serum concentration of Primaquine can be increased when it is combined with Pravastatin. | 72 | [
[
[
350,
95,
417
]
],
[
[
350,
6,
4590
],
[
4590,
160,
417
]
],
[
[
350,
21,
28613
],
[
28613,
175,
417
]
],
[
[
350,
180,
161
],
[
161,
... | [
[
[
"Pravastatin",
"{u} may increase the serum concentration of {v}",
"Primaquine"
]
],
[
[
"Pravastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Primaquine"
]
],
[
... | Pravastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Primaquine (Compound)
Pravastatin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Primaquine (Compound)
Pravastatin can increase the metabolism of Primidone and Primidone can increase the metabolism of Primaquine
P... |
DB00661 | DB00205 | 482 | 1,382 | Verapamil | Pyrimethamine | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. | The metabolism of Pyrimethamine can be decreased when combined with Verapamil. | 46 | [
[
[
482,
69,
1382
]
],
[
[
482,
6,
18777
],
[
18777,
160,
1382
]
],
[
[
482,
7,
6077
],
[
6077,
172,
1382
]
],
[
[
482,
21,
28448
],
[
284... | [
[
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Pyrimethamine"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pyrimethamine"
]
],
[
[
... | Verapamil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pyrimethamine (Compound)
Verapamil (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is downregulated by Pyrimethamine (Compound)
Verapamil (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Pyrimetha... |
DB00708 | DB01587 | 510 | 358 | Sufentanil | Ketazolam | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America. | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam. | 48 | [
[
[
510,
71,
358
]
],
[
[
510,
71,
552
],
[
552,
1,
358
]
],
[
[
510,
71,
259
],
[
259,
155,
358
]
],
[
[
510,
6,
4590
],
[
4590,
16... | [
[
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketazolam"
]
],
[
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methsuximide"
],
[
"Methsuximide",
"{u} ... | Sufentanil may increase the severity of adverse effects when combined with Methsuximide and Methsuximide (Compound) resembles Ketazolam (Compound)
Sufentanil may increase the severity of adverse effects when combined with Flunitrazepam and Flunitrazepam (Compound) resembles Ketazolam (Compound)
Sufentanil (Compound) bi... |
DB00308 | DB00557 | 1,317 | 1,262 | Ibutilide | Hydroxyzine | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Ibutilide may increase the QTc-prolonging activities of Hydroxyzine. | 19 | [
[
[
1317,
42,
1262
]
],
[
[
1317,
55,
955
],
[
955,
38,
1262
]
],
[
[
1317,
55,
971
],
[
971,
1,
1262
]
],
[
[
1317,
21,
28392
],
[
28392,... | [
[
[
"Ibutilide",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
]
],
[
[
"Ibutilide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase th... | Ibutilide may increase the severity of QTc prolonging effects when combined with Quetiapine and Quetiapine may increase the central nervous system depressant activities of Hydroxyzine
Ibutilide may increase the severity of QTc prolonging effects when combined with Zuclopenthixol and Zuclopenthixol (Compound) resembles ... |
DB00732 | DB01173 | 25 | 72 | Atracurium besylate | Orphenadrine | A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Orphenadrine. | 48 | [
[
[
25,
71,
72
]
],
[
[
25,
71,
44
],
[
44,
1,
72
]
],
[
[
25,
71,
469
],
[
469,
155,
72
]
],
[
[
25,
71,
984
],
[
984,
192,
7... | [
[
[
"Atracurium besylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orphenadrine"
]
],
[
[
"Atracurium besylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolterodine"
],
[
"Tolter... | Atracurium besylate may increase the severity of adverse effects when combined with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Atracurium besylate may increase the severity of adverse effects when combined with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Orphenadrine (Co... |
DB00231 | DB01267 | 312 | 1,007 | Temazepam | Paliperidone | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | The risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone. | 48 | [
[
[
312,
71,
1007
]
],
[
[
312,
71,
453
],
[
453,
1,
1007
]
],
[
[
312,
6,
4590
],
[
4590,
160,
1007
]
],
[
[
312,
21,
28442
],
[
28442,
... | [
[
[
"Temazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
]
],
[
[
"Temazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (... | Temazepam may increase the severity of adverse effects when combined with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Temazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paliperidone (Compound)
Temazepam (Compound) causes Aggression (Side Effect) and Aggression (Side Effe... |
DB11256 | DB00794 | 1,096 | 161 | Levomefolic acid | Primidone | Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma. It is transported across the membranes including the blood-brain barrier into various tissues where it plays an es... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | The serum concentration of the active metabolites of Primidone can be reduced when Primidone is used in combination with Levomefolic acid resulting in a loss in efficacy. | 10 | [
[
[
1096,
33,
161
]
],
[
[
1096,
97,
150
],
[
150,
26,
161
]
],
[
[
1096,
97,
156
],
[
156,
180,
161
]
],
[
[
1096,
97,
142
],
[
142,
... | [
[
[
"Levomefolic acid",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Primidone"
]
],
[
[
"Levomefolic acid",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase... | Levomefolic acid may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Primidone
Levomefolic acid may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Primidone
Levomefolic acid may decrease the serum concentration of Pheny... |
DB00752 | DB01253 | 63 | 376 | Tranylcypromine | Ergometrine | A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is ... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergometrine. | 48 | [
[
[
63,
71,
376
]
],
[
[
63,
223,
369
],
[
369,
41,
376
]
],
[
[
63,
225,
1303
],
[
1303,
155,
376
]
],
[
[
63,
225,
1456
],
[
1456,
... | [
[
[
"Tranylcypromine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ergometrine"
]
],
[
[
"Tranylcypromine",
"{u} may decrease the metabolism of {v}",
"Pergolide"
],
[
"Pergolide",
"{u} may increase the vasoconstr... | Tranylcypromine may decrease the metabolism of Pergolide and Pergolide may increase the vasoconstricting activities of Ergometrine
Tranylcypromine may increase the severity of adverse effects when combined with Methylergometrine and Methylergometrine (Compound) resembles Ergometrine (Compound)
Tranylcypromine may incre... |
DB01351 | DB00660 | 197 | 958 | Amobarbital | Metaxalone | A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | The risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone. | 48 | [
[
[
197,
71,
958
]
],
[
[
197,
21,
28384
],
[
28384,
175,
958
]
],
[
[
197,
184,
674
],
[
674,
30,
958
]
],
[
[
197,
192,
287
],
[
287,
... | [
[
[
"Amobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaxalone"
]
],
[
[
"Amobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (C... | Amobarbital (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metaxalone (Compound)
Amobarbital can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Metaxalone
Amobarbital may increase the central nervous system depressant activit... |
DB09295 | DB00788 | 1,442 | 621 | Talniflumate | Naproxen | Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. In addition, it is used in inflammatory conditions such as rheumatoid arthritis. Phase I trials with talniflumate for the treatment of cystic... | Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its ove... | The risk or severity of adverse effects can be increased when Talniflumate is combined with Naproxen. | 48 | [
[
[
1442,
71,
621
]
],
[
[
1442,
71,
388
],
[
388,
71,
621
]
],
[
[
1442,
71,
687
],
[
687,
28,
621
]
],
[
[
1442,
71,
582
],
[
582,
... | [
[
[
"Talniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Naproxen"
]
],
[
[
"Talniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{... | Talniflumate may increase the severity of adverse effects when combined with Flurbiprofen and Flurbiprofen may increase the severity of adverse effects when combined with Naproxen
Talniflumate may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulant activi... |
DB00727 | DB01144 | 1,354 | 1,357 | Nitroglycerin | Diclofenamide | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure ex... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Diclofenamide. | 48 | [
[
[
1354,
71,
1357
]
],
[
[
1354,
71,
1048
],
[
1048,
71,
1357
]
],
[
[
1354,
21,
28549
],
[
28549,
175,
1357
]
],
[
[
1354,
52,
828
],
[
... | [
[
[
"Nitroglycerin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Nitroglycerin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide... | Nitroglycerin may increase the severity of adverse effects when combined with Chlorothiazide and Chlorothiazide may increase the severity of adverse effects when combined with Diclofenamide
Nitroglycerin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Diclofenamide (Compound)
Nitroglycerin ... |
DB00514 | DB00780 | 440 | 53 | Dextromethorphan | Phenelzine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Dextromethorphan may increase the serotonergic activities of Phenelzine. | 63 | [
[
[
440,
86,
53
]
],
[
[
440,
86,
39
],
[
39,
155,
53
]
],
[
[
440,
86,
75
],
[
75,
1,
53
]
],
[
[
440,
6,
4590
],
[
4590,
160,
... | [
[
[
"Dextromethorphan",
"{u} may increase the serotonergic activities of {v}",
"Phenelzine"
]
],
[
[
"Dextromethorphan",
"{u} may increase the serotonergic activities of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compo... | Dextromethorphan may increase the serotonergic activities of Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Dextromethorphan may increase the serotonergic activities of Pargyline and Pargyline (Compound) resembles Phenelzine (Compound)
Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Ge... |
DB00783 | DB00379 | 352 | 544 | Estradiol | Mexiletine | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | The metabolism of Mexiletine can be decreased when combined with Estradiol. | 46 | [
[
[
352,
69,
544
]
],
[
[
352,
6,
12128
],
[
12128,
160,
544
]
],
[
[
352,
21,
28448
],
[
28448,
175,
544
]
],
[
[
352,
180,
161
],
[
161,... | [
[
[
"Estradiol",
"{u} may decrease the metabolism of {v}",
"Mexiletine"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Mexiletine"
]
],
[
[
"Est... | Estradiol (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Mexiletine (Compound)
Estradiol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Mexiletine (Compound)
Estradiol can increase the metabolism of Primidone and Primidone can increase the metabolism of Me... |
DB00956 | DB00231 | 1,083 | 312 | Hydrocodone | Temazepam | Hydrocodone is a synthetic opioid derivative of codeine. It is commonly used in combination with [acetaminophen] to control moderate to severe pain. Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations. Hydroc... | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Temazepam. | 15 | [
[
[
1083,
38,
312
]
],
[
[
1083,
38,
1267
],
[
1267,
155,
312
]
],
[
[
1083,
6,
4590
],
[
4590,
160,
312
]
],
[
[
1083,
21,
28585
],
[
285... | [
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Temazepam"
]
],
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} (C... | Hydrocodone may increase the central nervous system depressant activities of Lorazepam and Lorazepam (Compound) resembles Temazepam (Compound)
Hydrocodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temazepam (Compound)
Hydrocodone (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (... |
DB00679 | DB00961 | 653 | 962 | Thioridazine | Mepivacaine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168) | The risk or severity of adverse effects can be increased when Thioridazine is combined with Mepivacaine. | 48 | [
[
[
653,
71,
962
]
],
[
[
653,
223,
541
],
[
541,
71,
962
]
],
[
[
653,
7,
17657
],
[
17657,
161,
962
]
],
[
[
653,
18,
5353
],
[
5353,
... | [
[
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mepivacaine"
]
],
[
[
"Thioridazine",
"{u} may decrease the metabolism of {v}",
"Ropivacaine"
],
[
"Ropivacaine",
"{u} may increase the severity of ... | Thioridazine may decrease the metabolism of Ropivacaine and Ropivacaine may increase the severity of adverse effects when combined with Mepivacaine
Thioridazine (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Mepivacaine (Compound)
Thioridazine (Compound) downregulates CDC20 (Gene) and CDC20 ... |
DB00292 | DB09118 | 916 | 1,269 | Etomidate | Stiripentol | Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | The risk or severity of adverse effects can be increased when Etomidate is combined with Stiripentol. | 48 | [
[
[
916,
71,
1269
]
],
[
[
916,
192,
679
],
[
679,
38,
1269
]
],
[
[
916,
38,
1257
],
[
1257,
192,
1269
]
],
[
[
916,
192,
587
],
[
587,
... | [
[
[
"Etomidate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Stiripentol"
]
],
[
[
"Etomidate",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} m... | Etomidate may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Stiripentol
Etomidate may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system... |
DB06700 | DB00723 | 545 | 699 | Desvenlafaxine | Methoxamine | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. | Desvenlafaxine may increase the tachycardic activities of Methoxamine. | 84 | [
[
[
545,
107,
699
]
],
[
[
545,
107,
728
],
[
728,
155,
699
]
],
[
[
545,
107,
713
],
[
713,
71,
699
]
],
[
[
545,
213,
1344
],
[
1344,
... | [
[
[
"Desvenlafaxine",
"{u} may increase the tachycardic activities of {v}",
"Methoxamine"
]
],
[
[
"Desvenlafaxine",
"{u} may increase the tachycardic activities of {v}",
"Metaraminol"
],
[
"Metaraminol",
"{u} (Compound) resembles {v} (Compound... | Desvenlafaxine may increase the tachycardic activities of Metaraminol and Metaraminol (Compound) resembles Methoxamine (Compound)
Desvenlafaxine may increase the tachycardic activities of Midodrine and Midodrine may increase the severity of adverse effects when combined with Methoxamine
Desvenlafaxine may decrease the ... |
DB00656 | DB01247 | 175 | 42 | Trazodone | Isocarboxazid | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further... | The risk or severity of adverse effects can be increased when Trazodone is combined with Isocarboxazid. | 48 | [
[
[
175,
71,
42
]
],
[
[
175,
71,
151
],
[
151,
155,
42
]
],
[
[
175,
21,
28494
],
[
28494,
175,
42
]
],
[
[
175,
71,
33
],
[
33,
24... | [
[
[
"Trazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isocarboxazid"
]
],
[
[
"Trazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzyl alcohol"
],
[
"Benzyl alcohol",
... | Trazodone may increase the severity of adverse effects when combined with Benzyl alcohol and Benzyl alcohol (Compound) resembles Isocarboxazid (Compound)
Trazodone (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Isocarboxazid (Compound)
Trazodone may increa... |
DB01297 | DB00469 | 1,016 | 584 | Practolol | Tenoxicam | A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. | Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. | Practolol may decrease the antihypertensive activities of Tenoxicam. | 36 | [
[
[
1016,
59,
584
]
],
[
[
1016,
251,
164
],
[
164,
26,
584
]
],
[
[
1016,
59,
687
],
[
687,
28,
584
]
],
[
[
1016,
1,
1022
],
[
1022,
... | [
[
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Tenoxicam"
]
],
[
[
"Practolol",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
... | Practolol may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Tenoxicam
Practolol may decrease the antihypertensive activities of Nafamostat and Nafamostat may increase the anticoagulant activities of Tenoxicam
Practolol (Compound) resembles Pindolol (Compound) and Pin... |
DB01120 | DB00491 | 474 | 951 | Gliclazide | Miglitol | Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence o... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Gliclazide may increase the hypoglycemic activities of Miglitol. | 8 | [
[
[
474,
31,
951
]
],
[
[
474,
5,
18098
],
[
18098,
159,
951
]
],
[
[
474,
21,
28401
],
[
28401,
175,
951
]
],
[
[
474,
31,
862
],
[
862,
... | [
[
[
"Gliclazide",
"{u} may increase the hypoglycemic activities of {v}",
"Miglitol"
]
],
[
[
"Gliclazide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u} (Disease) is treated by {v} (Comp... | Gliclazide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Miglitol (Compound)
Gliclazide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Miglitol (Compound)
Gliclazide may increase the hypoglycemic activities of Trovaflo... |
DB01006 | DB00188 | 216 | 227 | Letrozole | Bortezomib | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | The metabolism of Bortezomib can be decreased when combined with Letrozole. | 46 | [
[
[
216,
69,
227
]
],
[
[
216,
6,
4590
],
[
4590,
160,
227
]
],
[
[
216,
21,
28410
],
[
28410,
175,
227
]
],
[
[
216,
191,
243
],
[
243,
... | [
[
[
"Letrozole",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bortezomib"
]
],
[
[
"Let... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound)
Letrozole (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Bortezomib (Compound)
Letrozole may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardioto... |
DB01107 | DB06595 | 1,406 | 422 | Methyprylon | Midostaurin | Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia. However, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited. Methyprylon was withdrawn from the U.S. market in Jun... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | The metabolism of Midostaurin can be decreased when combined with Methyprylon. | 46 | [
[
[
1406,
69,
422
]
],
[
[
1406,
69,
173
],
[
173,
26,
422
]
],
[
[
1406,
69,
527
],
[
527,
69,
422
]
],
[
[
1406,
69,
266
],
[
266,
... | [
[
[
"Methyprylon",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Methyprylon",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Midostaurin"
]
]... | Methyprylon may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Midostaurin
Methyprylon may decrease the metabolism of Bupropion and Bupropion may decrease the metabolism of Midostaurin
Methyprylon may decrease the metabolism of Indinavir and Indinavir may decrease the metabolism of ... |
DB01080 | DB00413 | 1,268 | 1,365 | Vigabatrin | Pramipexole | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the mos... | Vigabatrin may increase the sedative activities of Pramipexole. | 31 | [
[
[
1268,
54,
1365
]
],
[
[
1268,
21,
28404
],
[
28404,
175,
1365
]
],
[
[
1268,
71,
828
],
[
828,
206,
1365
]
],
[
[
1268,
225,
962
],
[
... | [
[
[
"Vigabatrin",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Vigabatrin",
"{u} (Compound) causes {v} (Side Effect)",
"Vascular purpura"
],
[
"Vascular purpura",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Vigabatrin (Compound) causes Vascular purpura (Side Effect) and Vascular purpura (Side Effect) is caused by Pramipexole (Compound)
Vigabatrin may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Pramipexole
Vigabatrin may increa... |
DB00861 | DB01600 | 844 | 4 | Diflunisal | Tiaprofenic acid | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the _arylpropionic acid_ (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs). | The risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid. | 48 | [
[
[
844,
71,
4
]
],
[
[
844,
155,
756
],
[
756,
155,
4
]
],
[
[
844,
71,
628
],
[
628,
71,
4
]
],
[
[
844,
155,
388
],
[
388,
71,
... | [
[
[
"Diflunisal",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiaprofenic acid"
]
],
[
[
"Diflunisal",
"{u} (Compound) resembles {v} (Compound)",
"Salsalate"
],
[
"Salsalate",
"{u} (Compound) resembles {v} (Compo... | Diflunisal (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Tiaprofenic acid (Compound)
Diflunisal may increase the severity of adverse effects when combined with Suprofen and Suprofen may increase the severity of adverse effects when combined with Tiaprofenic acid
Diflunisal (Compound) rese... |
DB01355 | DB00405 | 298 | 979 | Hexobarbital | Dexbrompheniramine | A barbiturate that is effective as a hypnotic and sedative. | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dexbrompheniramine. | 48 | [
[
[
298,
71,
979
]
],
[
[
298,
71,
281
],
[
281,
1,
979
]
],
[
[
298,
192,
72
],
[
72,
1,
979
]
],
[
[
298,
192,
587
],
[
587,
38,
... | [
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexbrompheniramine"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorpheniramine"
],
[
"Chlorphen... | Hexobarbital may increase the severity of adverse effects when combined with Chlorpheniramine and Chlorpheniramine (Compound) resembles Dexbrompheniramine (Compound)
Hexobarbital may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine (Compound) resembles Dexbrompheniramine (Compo... |
DB06697 | DB00502 | 539 | 245 | Artemether | Haloperidol | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | The metabolism of Haloperidol can be decreased when combined with Artemether. | 46 | [
[
[
539,
69,
245
]
],
[
[
539,
223,
55
],
[
55,
155,
245
]
],
[
[
539,
6,
8607
],
[
8607,
160,
245
]
],
[
[
539,
187,
161
],
[
161,
... | [
[
[
"Artemether",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Artemether",
"{u} may decrease the metabolism of {v}",
"Moclobemide"
],
[
"Moclobemide",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
]
... | Artemether may decrease the metabolism of Moclobemide and Moclobemide (Compound) resembles Haloperidol (Compound)
Artemether (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Haloperidol (Compound)
Artemether may reduce the serum concentration of the active metabolites of Primidone and Primidone can increase... |
DB08881 | DB06016 | 495 | 387 | Vemurafenib | Cariprazine | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | The serum concentration of Cariprazine can be decreased when it is combined with Vemurafenib. | 74 | [
[
[
495,
97,
387
]
],
[
[
495,
180,
161
],
[
161,
26,
387
]
],
[
[
495,
251,
142
],
[
142,
26,
387
]
],
[
[
495,
249,
150
],
[
150,
... | [
[
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Cariprazine"
]
],
[
[
"Vemurafenib",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Cariprazine"
... | Vemurafenib can increase the metabolism of Primidone and Primidone can increase the metabolism of Cariprazine
Vemurafenib may decrease the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Cariprazine
Vemurafenib may increase the serum concentration of Fosphenytoin and Fosphenytoin can incre... |
DB01186 | DB00187 | 369 | 1,034 | Pergolide | Esmolol | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic recep... | Pergolide may increase the atrioventricular blocking (AV block) activities of Esmolol. | 24 | [
[
[
369,
47,
1034
]
],
[
[
369,
47,
1027
],
[
1027,
225,
1034
]
],
[
[
369,
47,
911
],
[
911,
1,
1034
]
],
[
[
369,
47,
1026
],
[
1026,
... | [
[
[
"Pergolide",
"{u} may increase the atrioventricular blocking activities of {v}",
"Esmolol"
]
],
[
[
"Pergolide",
"{u} may increase the atrioventricular blocking activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the severity of... | Pergolide may increase the atrioventricular blocking activities of Sotalol and Sotalol may increase the severity of adverse effects when combined with Esmolol
Pergolide may increase the atrioventricular blocking activities of Oxprenolol and Oxprenolol (Compound) resembles Esmolol (Compound)
Pergolide may increase the a... |
DB00863 | DB00188 | 599 | 227 | Ranitidine | Bortezomib | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | The metabolism of Bortezomib can be decreased when combined with Ranitidine. | 46 | [
[
[
599,
69,
227
]
],
[
[
599,
6,
18777
],
[
18777,
160,
227
]
],
[
[
599,
7,
5499
],
[
5499,
161,
227
]
],
[
[
599,
18,
5334
],
[
5334,
... | [
[
[
"Ranitidine",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Bortezomib"
]
],
[
[
"R... | Ranitidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bortezomib (Compound)
Ranitidine (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Bortezomib (Compound)
Ranitidine (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Bortezomib (Compound)
Ranitidine... |
DB00712 | DB00678 | 388 | 567 | Flurbiprofen | Losartan | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | The metabolism of Losartan can be decreased when combined with Flurbiprofen. | 46 | [
[
[
388,
69,
567
]
],
[
[
388,
69,
239
],
[
239,
1,
567
]
],
[
[
388,
225,
1071
],
[
1071,
225,
567
]
],
[
[
388,
225,
174
],
[
174,
... | [
[
[
"Flurbiprofen",
"{u} may decrease the metabolism of {v}",
"Losartan"
]
],
[
[
"Flurbiprofen",
"{u} may decrease the metabolism of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[... | Flurbiprofen may decrease the metabolism of Valsartan and Valsartan (Compound) resembles Losartan (Compound)
Flurbiprofen may increase the severity of adverse effects when combined with Telmisartan and Telmisartan may increase the severity of adverse effects when combined with Losartan
Flurbiprofen may increase the sev... |
DB01036 | DB00322 | 44 | 1,252 | Tolterodine | Floxuridine | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | The metabolism of Floxuridine can be decreased when combined with Tolterodine. | 46 | [
[
[
44,
69,
1252
]
],
[
[
44,
21,
28501
],
[
28501,
175,
1252
]
],
[
[
44,
196,
394
],
[
394,
69,
1252
]
],
[
[
44,
69,
575
],
[
575,
... | [
[
[
"Tolterodine",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
],
[
[
"Tolterodine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",... | Tolterodine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Floxuridine (Compound)
Tolterodine may increase the QTc prolonging activities of Fluoxetine and Fluoxetine may decrease the metabolism of Floxuridine
Tolterodine may decrease the metabolism of Sulfisox... |
DB00655 | DB00685 | 124 | 862 | Estrone | Trovafloxacin | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | The risk or severity of adverse effects can be increased when Estrone is combined with Trovafloxacin. | 48 | [
[
[
124,
71,
862
]
],
[
[
124,
71,
863
],
[
863,
155,
862
]
],
[
[
124,
21,
28522
],
[
28522,
175,
862
]
],
[
[
124,
182,
219
],
[
219,
... | [
[
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trovafloxacin"
]
],
[
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (C... | Estrone may increase the severity of adverse effects when combined with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Estrone (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Trovafloxacin (Compound)
Estrone may increase the anticoagulant activities of Warfarin and ... |
DB00320 | DB06290 | 530 | 631 | Dihydroergotamine | Simeprevir | A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasa... | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | The serum concentration of Simeprevir can be increased when it is combined with Dihydroergotamine. | 72 | [
[
[
530,
95,
631
]
],
[
[
530,
6,
4590
],
[
4590,
160,
631
]
],
[
[
530,
21,
28463
],
[
28463,
175,
631
]
],
[
[
530,
180,
156
],
[
156,
... | [
[
[
"Dihydroergotamine",
"{u} may increase the serum concentration of {v}",
"Simeprevir"
]
],
[
[
"Dihydroergotamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Simeprevir"
]
... | Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simeprevir (Compound)
Dihydroergotamine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Simeprevir (Compound)
Dihydroergotamine can increase the metabolism of Carbamazepine and Carbamazepine can increase the metaboli... |
DB01136 | DB00501 | 248 | 886 | Carvedilol | Cimetidine | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | The serum concentration of Cimetidine can be increased when it is combined with Carvedilol. | 72 | [
[
[
248,
95,
886
]
],
[
[
248,
6,
13066
],
[
13066,
160,
886
]
],
[
[
248,
21,
28474
],
[
28474,
175,
886
]
],
[
[
248,
82,
421
],
[
421,
... | [
[
[
"Carvedilol",
"{u} may increase the serum concentration of {v}",
"Cimetidine"
]
],
[
[
"Carvedilol",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
],
[
[... | Carvedilol (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Cimetidine (Compound)
Carvedilol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Cimetidine (Compound)
Carvedilol may increase the hypotensive activities of Risedronic acid and Risedronic acid may increase the s... |
DB00238 | DB00223 | 173 | 113 | Nevirapine | Diflorasone | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin. | The serum concentration of Diflorasone can be decreased when it is combined with Nevirapine. | 74 | [
[
[
173,
97,
113
]
],
[
[
173,
26,
84
],
[
84,
1,
113
]
],
[
[
173,
97,
121
],
[
121,
155,
113
]
],
[
[
173,
97,
129
],
[
129,
1,
... | [
[
[
"Nevirapine",
"{u} may decrease the serum concentration of {v}",
"Diflorasone"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
],
[
"Fluticasone propionate",
"{u} (Compound) resembles {v} (Compound)... | Nevirapine can increase the metabolism of Fluticasone propionate and Fluticasone propionate (Compound) resembles Diflorasone (Compound)
Nevirapine may decrease the serum concentration of Desonide and Desonide (Compound) resembles Diflorasone (Compound)
Nevirapine may decrease the serum concentration of Fluocortolone an... |
DB01233 | DB01337 | 1,293 | 73 | Metoclopramide | Pancuronium | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | The therapeutic efficacy of Pancuronium can be decreased when used in combination with Metoclopramide. | 69 | [
[
[
1293,
92,
73
]
],
[
[
1293,
92,
40
],
[
40,
225,
73
]
],
[
[
1293,
21,
28463
],
[
28463,
175,
73
]
],
[
[
1293,
71,
18
],
[
18,
... | [
[
[
"Metoclopramide",
"{u} may decrease the therapeutic efficacy of {v}",
"Pancuronium"
]
],
[
[
"Metoclopramide",
"{u} may decrease the therapeutic efficacy of {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} may increase the severity of adverse eff... | Metoclopramide may decrease the therapeutic efficacy of Vecuronium and Vecuronium may increase the severity of adverse effects when combined with Pancuronium
Metoclopramide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Pancuronium (Compound)
Metoclopramide may increase the severity of adverse... |
DB00663 | DB01118 | 105 | 137 | Flumethasone | Amiodarone | Flumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammatio... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | The serum concentration of Amiodarone can be increased when it is combined with Flumethasone. | 72 | [
[
[
105,
95,
137
]
],
[
[
105,
21,
28448
],
[
28448,
175,
137
]
],
[
[
105,
251,
156
],
[
156,
26,
137
]
],
[
[
105,
182,
219
],
[
219,
... | [
[
[
"Flumethasone",
"{u} may increase the serum concentration of {v}",
"Amiodarone"
]
],
[
[
"Flumethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",... | Flumethasone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Amiodarone (Compound)
Flumethasone may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Amiodarone
Flumethasone may increase the anticoagulant activities of War... |
DB00648 | DB00588 | 1,080 | 84 | Mitotane | Fluticasone propionate | Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma an... | Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990. | The serum concentration of Fluticasone propionate can be decreased when it is combined with Mitotane. | 74 | [
[
[
1080,
97,
84
]
],
[
[
1080,
97,
113
],
[
113,
155,
84
]
],
[
[
1080,
97,
117
],
[
117,
1,
84
]
],
[
[
1080,
6,
18799
],
[
18799,
... | [
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Fluticasone propionate"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Diflorasone"
],
[
"Diflorasone",
"{u} (Compound) resembles {v} (Compound)",
... | Mitotane may decrease the serum concentration of Diflorasone and Diflorasone (Compound) resembles Fluticasone propionate (Compound)
Mitotane may decrease the serum concentration of Rimexolone and Rimexolone (Compound) resembles Fluticasone propionate (Compound)
Mitotane (Compound) binds SERPINA6 (Gene) and SERPINA6 (Ge... |
DB00794 | DB00975 | 161 | 736 | Primidone | Dipyridamole | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Primidone may increase the hypotensive activities of Dipyridamole. | 59 | [
[
[
161,
82,
736
]
],
[
[
161,
21,
29099
],
[
29099,
175,
736
]
],
[
[
161,
97,
560
],
[
560,
28,
736
]
],
[
[
161,
26,
238
],
[
238,
... | [
[
[
"Primidone",
"{u} may increase the hypotensive activities of {v}",
"Dipyridamole"
]
],
[
[
"Primidone",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dipyridamol... | Primidone (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Dipyridamole (Compound)
Primidone may decrease the serum concentration of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Dipyridamole
Primidone can increase the metabolism of Nimesulide and Nimesulide may ... |
DB01244 | DB00502 | 190 | 245 | Bepridil | Haloperidol | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | The metabolism of Haloperidol can be decreased when combined with Bepridil. | 46 | [
[
[
190,
69,
245
]
],
[
[
190,
236,
55
],
[
55,
155,
245
]
],
[
[
190,
6,
5406
],
[
5406,
160,
245
]
],
[
[
190,
21,
28515
],
[
28515,
... | [
[
[
"Bepridil",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Bepridil",
"{u} may increase the hypotensive activities of {v}",
"Moclobemide"
],
[
"Moclobemide",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
... | Bepridil may increase the hypotensive activities of Moclobemide and Moclobemide (Compound) resembles Haloperidol (Compound)
Bepridil (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Haloperidol (Compound)
Bepridil (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Haloperidol (... |
DB01053 | DB00684 | 881 | 906 | Benzylpenicillin | Tobramycin | Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible o... | Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cys... | The serum concentration of Tobramycin can be decreased when it is combined with Benzylpenicillin. | 74 | [
[
[
881,
97,
906
]
],
[
[
881,
97,
904
],
[
904,
155,
906
]
],
[
[
881,
21,
28651
],
[
28651,
175,
906
]
],
[
[
881,
92,
1572
],
[
1572,
... | [
[
[
"Benzylpenicillin",
"{u} may decrease the serum concentration of {v}",
"Tobramycin"
]
],
[
[
"Benzylpenicillin",
"{u} may decrease the serum concentration of {v}",
"Paromomycin"
],
[
"Paromomycin",
"{u} (Compound) resembles {v} (Compound)",... | Benzylpenicillin may decrease the serum concentration of Paromomycin and Paromomycin (Compound) resembles Tobramycin (Compound)
Benzylpenicillin (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Tobramycin (Compound)
Benzylpenicillin may decrease the therapeutic ef... |
DB00287 | DB00492 | 1,051 | 656 | Travoprost | Fosinopril | Travoprost is a synthetic isopropyl ester prodrug of a prostaglandin F2alpha (F2α) analogue and selective FP prostanoid receptor agonist. It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension. Unlike other prostaglandin analogues, travoprost demonstrates full agonism and high select... | Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angio... | Travoprost may increase the hypotensive activities of Fosinopril. | 59 | [
[
[
1051,
82,
656
]
],
[
[
1051,
82,
315
],
[
315,
225,
656
]
],
[
[
1051,
82,
549
],
[
549,
155,
656
]
],
[
[
1051,
21,
28506
],
[
28506,... | [
[
[
"Travoprost",
"{u} may increase the hypotensive activities of {v}",
"Fosinopril"
]
],
[
[
"Travoprost",
"{u} may increase the hypotensive activities of {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects wh... | Travoprost may increase the hypotensive activities of Enalapril and Enalapril may increase the severity of adverse effects when combined with Fosinopril
Travoprost may increase the hypotensive activities of Spirapril and Spirapril (Compound) resembles Fosinopril (Compound)
Travoprost (Compound) causes Hypertension (Sid... |
DB00280 | DB01026 | 589 | 496 | Disopyramide | Ketoconazole | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconaz... | The serum concentration of Ketoconazole can be increased when it is combined with Disopyramide. | 72 | [
[
[
589,
95,
496
]
],
[
[
589,
69,
479
],
[
479,
69,
496
]
],
[
[
589,
6,
4590
],
[
4590,
160,
496
]
],
[
[
589,
21,
28474
],
[
28474,
... | [
[
[
"Disopyramide",
"{u} may increase the serum concentration of {v}",
"Ketoconazole"
]
],
[
[
"Disopyramide",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may decrease the metabolism of {v}",
"Ketoco... | Disopyramide may decrease the metabolism of Posaconazole and Posaconazole may decrease the metabolism of Ketoconazole
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Disopyramide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ketoco... |
DB00327 | DB12332 | 260 | 381 | Hydromorphone | Rucaparib | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | The metabolism of Rucaparib can be decreased when combined with Hydromorphone. | 46 | [
[
[
260,
69,
381
]
],
[
[
260,
180,
177
],
[
177,
26,
381
]
],
[
[
260,
225,
46
],
[
46,
69,
381
]
],
[
[
260,
69,
143
],
[
143,
223... | [
[
[
"Hydromorphone",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Hydromorphone",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rucaparib"
]
... | Hydromorphone can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Rucaparib
Hydromorphone may increase the severity of adverse effects when combined with Solifenacin and Solifenacin may decrease the metabolism of Rucaparib
Hydromorphone may decrease the metabolism of Erythromycin a... |
DB00153 | DB01072 | 182 | 564 | Ergocalciferol | Atazanavir | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | The metabolism of Atazanavir can be decreased when combined with Ergocalciferol. | 46 | [
[
[
182,
69,
564
]
],
[
[
182,
69,
429
],
[
429,
1,
564
]
],
[
[
182,
6,
4590
],
[
4590,
160,
564
]
],
[
[
182,
21,
28446
],
[
28446,
... | [
[
[
"Ergocalciferol",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Ergocalciferol",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
... | Ergocalciferol may decrease the metabolism of Lopinavir and Lopinavir (Compound) resembles Atazanavir (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atazanavir (Compound)
Ergocalciferol (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Atazanavir (C... |
DB00645 | DB01563 | 982 | 943 | Dyclonine | Chloral hydrate | Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products. | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate. | 48 | [
[
[
982,
71,
943
]
],
[
[
982,
184,
674
],
[
674,
30,
943
]
],
[
[
982,
38,
1264
],
[
1264,
192,
943
]
],
[
[
982,
192,
1083
],
[
1083,
... | [
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chloral hydrate"
]
],
[
[
"Dyclonine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therap... | Dyclonine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Chloral hydrate
Dyclonine may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Chloral hydr... |
DB00818 | DB00622 | 280 | 158 | Propofol | Nicardipine | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | The metabolism of Nicardipine can be decreased when combined with Propofol. | 46 | [
[
[
280,
69,
158
]
],
[
[
280,
69,
516
],
[
516,
225,
158
]
],
[
[
280,
225,
435
],
[
435,
236,
158
]
],
[
[
280,
225,
329
],
[
329,
... | [
[
[
"Propofol",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Propofol",
"{u} may decrease the metabolism of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
... | Propofol may decrease the metabolism of Felodipine and Felodipine may increase the severity of adverse effects when combined with Nicardipine
Propofol may increase the severity of adverse effects when combined with Nilvadipine and Nilvadipine may increase the hypotensive activities of Nicardipine
Propofol may increase ... |
DB08932 | DB09120 | 1,068 | 1,119 | Macitentan | Zucapsaicin | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain. It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articu... | The metabolism of Zucapsaicin can be decreased when combined with Macitentan. | 46 | [
[
[
1068,
69,
1119
]
],
[
[
1068,
69,
613
],
[
613,
69,
1119
]
],
[
[
1068,
236,
1037
],
[
1037,
69,
1119
]
],
[
[
1068,
95,
764
],
[
764,... | [
[
[
"Macitentan",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Macitentan",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
]... | Macitentan may decrease the metabolism of Ticlopidine and Ticlopidine may decrease the metabolism of Zucapsaicin
Macitentan may increase the hypotensive activities of Betaxolol and Betaxolol may decrease the metabolism of Zucapsaicin
Macitentan may increase the serum concentration of Dasatinib and Dasatinib may decreas... |
DB00186 | DB00754 | 1,267 | 821 | Lorazepam | Ethotoin | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethotoin. | 48 | [
[
[
1267,
71,
821
]
],
[
[
1267,
71,
161
],
[
161,
155,
821
]
],
[
[
1267,
71,
164
],
[
164,
71,
821
]
],
[
[
1267,
21,
28463
],
[
28463,
... | [
[
[
"Lorazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
],
[
[
"Lorazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound... | Lorazepam may increase the severity of adverse effects when combined with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Lorazepam may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital may increase the severity of adverse effects when combined with Ethotoin
Lo... |
DB00752 | DB00675 | 63 | 568 | Tranylcypromine | Tamoxifen | A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is ... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy. | 10 | [
[
[
63,
33,
568
]
],
[
[
63,
225,
469
],
[
469,
155,
568
]
],
[
[
63,
223,
330
],
[
330,
155,
568
]
],
[
[
63,
247,
149
],
[
149,
15... | [
[
[
"Tranylcypromine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
],
[
[
"Tranylcypromine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dextropropoxyphene"
],
[
"Dextroprop... | Tranylcypromine may increase the severity of adverse effects when combined with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Tamoxifen (Compound)
Tranylcypromine may decrease the metabolism of Ospemifene and Ospemifene (Compound) resembles Tamoxifen (Compound)
Tranylcypromine may increase the hyperten... |
DB04552 | DB01021 | 774 | 1,045 | Niflumic acid | Trichlormethiazide | Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Niflumic acid. | 69 | [
[
[
774,
92,
1045
]
],
[
[
774,
92,
1048
],
[
1048,
82,
1045
]
],
[
[
774,
92,
1326
],
[
1326,
1,
1045
]
],
[
[
774,
92,
1072
],
[
1072,
... | [
[
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Trichlormethiazide"
]
],
[
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may increase the hypotensiv... | Niflumic acid may decrease the therapeutic efficacy of Chlorothiazide and Chlorothiazide may increase the hypotensive activities of Trichlormethiazide
Niflumic acid may decrease the therapeutic efficacy of Methyclothiazide and Methyclothiazide (Compound) resembles Trichlormethiazide (Compound)
Niflumic acid may decreas... |
DB01043 | DB00392 | 1,120 | 69 | Memantine | Profenamine | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Profenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada. In the US, the marketing of profenamine has been discontinued. | The therapeutic efficacy of Profenamine can be decreased when used in combination with Memantine. | 69 | [
[
[
1120,
92,
69
]
],
[
[
1120,
6,
3832
],
[
3832,
160,
69
]
],
[
[
1120,
92,
28
],
[
28,
24,
69
]
],
[
[
1120,
92,
44
],
[
44,
225,... | [
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Profenamine"
]
],
[
[
"Memantine",
"{u} (Compound) binds {v} (Gene)",
"GRIN3A"
],
[
"GRIN3A",
"{u} (Gene) is bound by {v} (Compound)",
"Profenamine"
]
],
[
... | Memantine (Compound) binds GRIN3A (Gene) and GRIN3A (Gene) is bound by Profenamine (Compound)
Memantine may decrease the therapeutic efficacy of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Profenamine
Memantine may decrease the therapeutic efficacy of Tolterodine and Tolterodine may... |
DB00264 | DB00749 | 576 | 460 | Metoprolol | Etodolac | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Metoprolol may decrease the antihypertensive activities of Etodolac. | 36 | [
[
[
576,
59,
460
]
],
[
[
576,
21,
28501
],
[
28501,
175,
460
]
],
[
[
576,
236,
164
],
[
164,
26,
460
]
],
[
[
576,
251,
177
],
[
177,
... | [
[
[
"Metoprolol",
"{u} may decrease the antihypertensive activities of {v}",
"Etodolac"
]
],
[
[
"Metoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} ... | Metoprolol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Etodolac (Compound)
Metoprolol may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Etodolac
Metoprolol may decrease the serum concentration of Rifap... |
DB00564 | DB00323 | 156 | 975 | Carbamazepine | Tolcapone | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Tolcapone. | 48 | [
[
[
156,
71,
975
]
],
[
[
156,
26,
313
],
[
313,
155,
975
]
],
[
[
156,
6,
7128
],
[
7128,
160,
975
]
],
[
[
156,
21,
28512
],
[
28512,
... | [
[
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
],
[
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Niclosamide"
],
[
"Niclosamide",
"{u} (Compound) resembles {v} (Com... | Carbamazepine can increase the metabolism of Niclosamide and Niclosamide (Compound) resembles Tolcapone (Compound)
Carbamazepine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tolcapone (Compound)
Carbamazepine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tolcapone (C... |
DB00813 | DB13872 | 961 | 910 | Fentanyl | Lormetazepam | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia. It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations. | The risk or severity of adverse effects can be increased when Fentanyl is combined with Lormetazepam. | 48 | [
[
[
961,
71,
910
]
],
[
[
961,
38,
1264
],
[
1264,
192,
910
]
],
[
[
961,
192,
679
],
[
679,
38,
910
]
],
[
[
961,
54,
1046
],
[
1046,
... | [
[
[
"Fentanyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Fentanyl",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"... | Fentanyl may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Lormetazepam
Fentanyl may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous... |
DB08875 | DB01211 | 688 | 1,088 | Cabozantinib | Clarithromycin | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | The serum concentration of Clarithromycin can be increased when it is combined with Cabozantinib. | 72 | [
[
[
688,
95,
1088
]
],
[
[
688,
69,
143
],
[
143,
196,
1088
]
],
[
[
688,
95,
528
],
[
528,
196,
1088
]
],
[
[
688,
69,
795
],
[
795,
... | [
[
[
"Cabozantinib",
"{u} may increase the serum concentration of {v}",
"Clarithromycin"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v... | Cabozantinib may decrease the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Clarithromycin
Cabozantinib may increase the serum concentration of Telithromycin and Telithromycin may increase the QTc prolonging activities of Clarithromycin
Cabozantinib may decrease the metabolis... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.